Results 81 to 90 of about 92,115 (273)

The Influence of Neoadjuvant Chemoradiotherapy on Muscle Mass in Patients with Rectal Cancer

World Journal of Colorectal Surgery, 2019
Background: The psoas major muscle accurately represents overall skeletal muscle mass. The skeletal muscle mass volume is related to outcomes in multiple surgical procedures including colorectal cancer.
Gregory Simpson, Thomas Marks, Sarah Blacker, Conor Magee, Jeremy Wilson   +4 more
doaj   +1 more source

Adjuvant Chemotherapy Regimens in Resected Biliary Tract Cancers: National, Comparative, Observational Study (TOG/GI‐SAFRADJU‐2501)

International Journal of Cancer, EarlyView.
ABSTRACT The recommended adjuvant chemotherapy (adj‐ChT) regimen for resected biliary tract cancers (BTC) is capecitabine (Cape); yet, the recommendation is based on limited evidence. Although varied adj‐ChTs have been employed in practice, robust real‐world data is scarce. We conducted a national, multicenter, hospital‐based registry study to evaluate
Erman Akkus, Mehmet Kayaalp, Müzeyyen Aslı Ergözoğlu, Ilgın Koç Kuş, Doğan Bayram, Bilgeşah Kılıçtaş, Emel Ayvaz Güneyin, Ali Kalem, Haydar Temizyürek, Mehmet Mutlu Çatlı, Mehmet Sinan Akarca, Maral Martin Mıldanoğlu, Görkem Turhan, Mahmut Kara, Hacı Arak, Feyza Arslan Tan, Burak Paçacı, Berkay Yeşilyurt, Orhun Akdoğan, Emine Bihter Çetin, Selahattin Çelik, Fatma Keskin Uzundere, Elif Şahin, Zehra Sadak Öcal, Lamia Şeker Can, Bahadır Köylü, Mehmet Cem Fidan, Esmanur Kaplan Tüzün, Teoman Şakalar, Elif Sertesen Çamöz, Haydar Çağatay Yüksel, Onur Yazdan Balçık, Pınar Peker, Mehmet Yılmaz, Şeymanur Ala Enli, Erdem Kölemen, Sibel Oyucu Orhan, Yakup Düzköprü, Mustafa Ersoy, Tuğba Akın Telli, Mesut Yılmaz, Yusuf İlhan, Atila Yıldırım, Ramazan Coşar, Müslih Ürün, Arif Hakan Önder, Murat Araz, Ertuğrul Bayram, Havva Yeşil Çınkır, Ali Alkan, Mustafa Gürbüz, Nilüfer Avcı, Fatma Paksoy Türköz, İsmail Oğuz Kara, Fatih Köse, İlkay Tuğba Ünek, Ahmet Bilici, Öznur Bal, Şuayib Yalçın, Lorenza Rimassa, Hatime Arzu Yaşar   +60 more
wiley   +1 more source

[Neoadjuvant chemoradiotherapy in gallbladder cancer].

Revista medica de Chile, 2005
Gallbladder cancer is generally associated with a poor prognosis, being local recurrence the main pattern of failure.To evaluate neoadjuvant chemoradiation as a means to improve the prognosis in gallbladder cancer.Twenty three gallbladder cancer patients were prospectively treated between June 1993 and September 1999 in the Temuco Regional Hospital ...
Xabier, de Aretxabala, Héctor, Losada, Javier, Mora, Iván, Roa, Luis, Burgos, Eduardo, Yáñez, Ingrid, Quijada, Juan Carlos, Roa   +7 more
openaire   +1 more source

Neoadjuvant chemoradiotherapy for esophageal/gastroesophageal carcinoma.

Journal of gastrointestinal oncology, 2013
Esophageal/gastroesophageal junction (GEJ) adenocarcinoma is increasingly treated with trimodality therapy. We present our experience using carboplatin/paclitaxel and radiotherapy followed by surgery.Consecutive patients with distal esophageal/GEJ adenocarcinoma (≥T2 or N+) treated from July 2010 to October 2011 were identified.
Timothy A, Platz, Steven J, Nurkin, Mei Ka, Fong, Adrienne, Groman, Leayn, Flaherty, Usha, Malhotra, Charles M, Levea, Sai, Yendamuri, Graham W, Warren, Hector R, Nava, Kilian S, May   +10 more
openaire   +2 more sources

Neoadjuvant Chemotherapy and Adjuvant Chemoradiotherapy in the Treatment of Gastric Adenocarcinomas [PDF]

, 2018
Purpose: Gastric cancer is the third leading cause of cancer-related death worldwide. From 1974-1975, patients who received gastric resection only had a 5-year survival rate of 15.3%.16 With the introduction of chemoradiotherapy, the 5-year survival rate
Feldman, James
core   +1 more source

Tolerability of Adjuvant Nivolumab in Esophageal or Gastroesophageal Junction Cancer: A Real‐World Study

International Journal of Cancer, EarlyView.
ABSTRACT Adjuvant nivolumab is approved for esophageal or gastroesophageal junction cancer after neoadjuvant chemoradiotherapy and resection. In the CheckMate‐577 trial, Grade 3–5 nivolumab‐related adverse events (AEs) occurred in 5% of patients, with early discontinuation due to toxicity in 9%. However, real‐world data on immunotherapy‐related adverse
Michelle Koops van ’t Jagt, Anniek Strijdhorst, Tamara Jessica Huizer, Esther Albertien Kleibeuker, Sarah Derks, Bianca Mostert, Hanneke van Laarhoven, Jacco Juri de Haan   +7 more
wiley   +1 more source

Expression of Transketolase like gene 1 (TKTL1) predicts disease-free survival in patients with locally advanced rectal cancer receiving neoadjuvant chemoradiotherapy

BMC Cancer, 2011
Background For patients with locally advanced rectal cancer (LARC) neoadjuvant chemoradiotherapy is recommended as standard therapy. So far, no predictive or prognostic molecular factors for patients undergoing multimodal treatment are established ...
Hofmann Wolf-Karsten, Wenz Frederik, Post Stefan, Kienle Peter, Kähler Georg, Gencer Deniz, Bohn Beatrice, Ströbel Philipp, Horisberger Karoline, Schwaab Juliana, Hofheinz Ralf-Dieter, Erben Philipp   +11 more
doaj   +1 more source

Clinical Translation of Patient‐Derived Organoids: Perspectives for Personalized Therapy in Cancer

International Journal of Cancer, EarlyView.
ABSTRACT Patient‐derived organoids (PDO) are accelerating precision medicine. These biological platforms allow for the autologous in vitro expansion of material from cancer patients in a considerably short period of time. These three‐dimensional models can faithfully recapitulate aspects of tissue heterogeneity, architecture, and relevant cellular ...
Haiyan Yue, Daniele Carchidi, Philipp Schmucker, Roland Seiler, Bernhard Kiss, Catarina Macedo‐Silva, Marianna Kruithof‐de Julio   +6 more
wiley   +1 more source

Surgery alone versus neoadjuvant chemoradiotherapy followed by surgery in patients with stage T2N0M0 esophageal cancer

Scientific Reports
To compare the survival outcomes of patients with stage T2N0M0 esophageal cancer treated with surgery alone versus those treated with neoadjuvant chemoradiotherapy followed by surgery.
Yan Lin, Shou-Feng Wang, Huan-Wei Liang, Yang Liu, Wei Huang, Xin-Bin Pan   +5 more
doaj   +1 more source

Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis

, 2011
Background In a previous meta-analysis, we identified a survival benefit from neoadjuvant chemotherapy or chemoradiotherapy before surgery in patients with resectable oesophageal carcinoma.
Burmeister, Bryan H., Gebski, Val, Zalcberg, John R., Bryan H Burmeister, Val Gebski, Barbour, Andrew, Andrew Barbour, Smithers, B. Mark, for the Australasian Gastro-Intestinal Trials Group, R John Simes, Simes, R. John, Sjoquist, Katrin M., B Mark Smithers, John R Zalcberg, Katrin M Sjoquist   +14 more
core   +1 more source